Sugi Predict

Sugi Predict / Compounds / SCHEMBL8004755

SCHEMBL8004755

SCHEMBL8004755

Cc1ccnn1C1CCCCO1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 4/20 0.53
▸ CYP4A11 Q02928 4/20 0.53
▸ ATR Q13535 11/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ HCRTR1 O43613 1/20 0.39
▸ HCRTR2 O43614 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ RXRA P19793 1/20 0.38
▸ RXRB P28702 1/20 0.38
▸ RXRG P48443 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21437982 0.81 CYP4F2 (0.49) CYP4F2CYP4A11ATRALDH1A1LMNA
SCHEMBL21438537 0.80 CYP4F2 (0.48) CYP4F2CYP4A11ATRALDH1A1LMNA
SCHEMBL12693554 0.79 CYP4F2 (0.47) CYP4F2CYP4A11ATRALDH1A1LMNA
SCHEMBL19204923 0.79 CYP4F2 (0.53) CYP4F2CYP4A11ATRALDH1A1LMNA
SCHEMBL18438313 0.79 CYP4F2 (0.50) CYP4F2CYP4A11ATRALDH1A1LMNA
SCHEMBL24173879 0.79 ALDH1A1 (0.49) CYP4F2CYP4A11ATRALDH1A1LMNA
SCHEMBL18133767 0.79 CYP4F2 (0.47) CYP4F2CYP4A11ATRALDH1A1LMNA
SCHEMBL18758225 0.79 CYP4F2 (0.47) CYP4F2CYP4A11ATRALDH1A1LMNA
SCHEMBL22951244 0.79 CYP4F2 (0.47) CYP4F2CYP4A11ATRALDH1A1LMNA
SCHEMBL21185040 0.79 CYP4F2 (0.47) CYP4F2CYP4A11ATRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360135-A1 IMIDAZO[1,2-B]PYRIDAZINYL COMPOUNDS AND USES THEREOF SUMITOMO PHARMA ONCOLOGY INC (US) 2024-10-31 — — US disclosed
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2024-10-29 — — US disclosed
US-12037344-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC (US) 2024-07-16 — — US disclosed
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-09-21 — — US disclosed
WO-2023116865-A1 PYRAZOLE-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 优领医药科技（上海）有限公司 2023-06-29 — — WO disclosed
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2023-05-11 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2023-02-09 — — US disclosed
WO-2023010102-A1 IMIDAZO[1,2-B]PYRIDAZINYL COMPOUNDS AND USES THEREOF SUMITOMO PHARMA ONCOLOGY, INC. (US) 2023-02-02 — — WO disclosed
EP-4108663-A1 SUBSTITUTED ARYL COMPOUND Simcere Pharmaceutical Co., Ltd. (CN) 2022-12-28 — — EP disclosed
WO-2019013244-A1 METHOD FOR PRODUCING (2S)-2-[(1H-PYRAZOL-1-YL)METHYL]-1,3-OXAZINANE DERIVATIVE 大正製薬株式会社 2019-01-17 — — WO disclosed
EP-3419978-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS Pfizer Inc (US) 2019-01-02 — — EP disclosed
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives PFIZER INC. (US) 2018-12-04 — — US disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
WO-2017133667-A1 PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF SAVIRA PHARMACEUTICALS GMBH (AT) 2017-08-10 — — WO disclosed
WO-2009151991-A1 PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2009-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CBR1 CYP4F2 429/4885CYP4A11 261/4885ATR 2224/4885
US-12037344-B2 NLRP3 modulators NLRP3, NLRP1, PYCARD CYP4F2 1583/4885CYP4A11 242/4885ATR 3043/4885
US-20230045252-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 CYP4F2 502/4885CYP4A11 284/4885ATR 2449/4885
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives JAK1, JAK2, JAK3 CYP4F2 2282/4885CYP4A11 670/4885ATR 486/4885
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ATR, CHEK1, CHEK2 CYP4F2 4245/4885CYP4A11 4459/4885ATR 1/4885
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 CYP4F2 502/4885CYP4A11 284/4885ATR 2449/4885
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND RAD51, FANCI, BLM CYP4F2 1801/4885CYP4A11 689/4885ATR 144/4885
US-20240360135-A1 IMIDAZO[1,2-B]PYRIDAZINYL COMPOUNDS AND USES THEREOF REN, IL1B, COL1A1 CYP4F2 42/4885CYP4A11 77/4885ATR 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.